Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05030831 · ClinicalTrials.gov registry record · Phase 1
Evaluation of Safety, Tolerability, and Efficacy of INZ-701 in Adults With ABCC6 Deficiency Causing PXE
A Phase 1 study, sponsored by Inozyme Pharma.
- Completed
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
NCT05030831 is a Phase 1 study that has completed, run by Inozyme Pharma. The registered enrollment target is 10 participants.
The verdict
NCT05030831, a Phase 1 study, has completed, sponsored by Inozyme Pharma.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics PD) of multiple ascending doses of INZ-701, an ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) recombinant fusion protein, for the treatment of ABCC6 Deficiency. The goal of the study is to identify a dose regimen for further clinical development in the treatment of ABCC6 Deficiency.
Interventions
- DRUG INZ-701
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2022-04-11 |
| Est. Completion | 2024-07-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05030831
The ClinicalTrials.gov registry entry for NCT05030831 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Inozyme Pharma, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which INZ-701 is the first listed.
NCT05030831 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05030831 about?
NCT05030831 is a clinical study titled "Evaluation of Safety, Tolerability, and Efficacy of INZ-701 in Adults With ABCC6 Deficiency Causing PXE". The purpose of this study is to assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics PD) of multiple ascending doses of INZ-701, an ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) recombinant fusion protein, for the treatment of ABCC6 Deficiency. The goal of the st...
What is the current status of trial NCT05030831?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2022-04-11. Estimated completion is 2024-07-09.
What interventions are being tested in trial NCT05030831?
The interventions under investigation include: INZ-701 (DRUG).
Who is sponsoring clinical trial NCT05030831?
This trial is sponsored by Inozyme Pharma, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.